Company Quick10K Filing
Sorrento Therapeutics
10-Q 2020-03-31 Filed 2020-05-11
10-K 2019-12-31 Filed 2020-03-03
10-Q 2019-09-30 Filed 2019-11-12
10-Q 2019-06-30 Filed 2019-08-09
10-Q 2019-03-31 Filed 2019-05-15
10-K 2018-12-31 Filed 2019-03-15
10-Q 2018-09-30 Filed 2018-11-09
10-Q 2018-06-30 Filed 2018-08-09
10-Q 2018-03-31 Filed 2018-05-10
10-K 2017-12-31 Filed 2018-03-16
10-Q 2017-09-30 Filed 2017-11-09
10-Q 2017-06-30 Filed 2017-08-09
10-Q 2017-03-31 Filed 2017-05-15
10-K 2016-12-31 Filed 2017-03-22
10-Q 2016-09-30 Filed 2016-11-09
10-Q 2016-06-30 Filed 2016-08-08
10-Q 2016-03-31 Filed 2016-05-10
10-K 2015-12-31 Filed 2016-03-15
10-Q 2015-09-30 Filed 2015-11-16
10-Q 2015-06-30 Filed 2015-08-07
10-Q 2015-03-31 Filed 2015-05-05
10-K 2014-12-31 Filed 2015-03-16
10-Q 2014-09-30 Filed 2014-11-04
10-Q 2014-06-30 Filed 2014-08-06
10-Q 2014-03-31 Filed 2014-05-14
10-K 2013-12-31 Filed 2014-04-01
10-Q 2013-09-30 Filed 2013-11-14
10-Q 2013-06-30 Filed 2013-08-13
10-Q 2013-03-31 Filed 2013-05-15
10-K 2012-12-31 Filed 2013-03-25
10-Q 2012-09-30 Filed 2012-11-08
10-Q 2012-06-30 Filed 2012-08-14
10-Q 2012-03-31 Filed 2012-05-15
10-K 2011-12-31 Filed 2012-03-30
10-Q 2011-09-30 Filed 2011-11-08
10-Q 2011-06-30 Filed 2011-08-12
10-Q 2011-03-31 Filed 2011-05-12
10-K 2010-12-31 Filed 2011-03-18
10-Q 2010-09-30 Filed 2010-11-08
10-Q 2010-06-30 Filed 2010-08-12
10-Q 2010-03-31 Filed 2010-05-14
10-K 2009-12-31 Filed 2010-03-25
8-K 2020-07-24 Other Events, Exhibits
8-K 2020-07-23 Enter Agreement, Other Events, Exhibits
8-K 2020-07-20 Other Events, Exhibits
8-K 2020-07-13 Enter Agreement, Exhibits
8-K 2020-07-01 Other Events, Exhibits
8-K 2020-06-24 Accountant, Exhibits
8-K 2020-06-12
8-K 2020-06-05
8-K 2020-05-21
8-K 2020-05-15
8-K 2020-04-27
8-K 2020-03-31
8-K 2020-03-20
8-K 2020-03-05
8-K 2020-02-27
8-K 2020-02-10
8-K 2020-01-27
8-K 2020-01-10
8-K 2019-12-16
8-K 2019-12-06
8-K 2019-11-25
8-K 2019-10-09
8-K 2019-10-07
8-K 2019-10-01
8-K 2019-10-01
8-K 2019-09-23
8-K 2019-09-20
8-K 2019-08-12
8-K 2019-08-12
8-K 2019-07-02
8-K 2019-06-28
8-K 2019-06-20
8-K 2019-06-19
8-K 2019-06-17
8-K 2019-06-17
8-K 2019-06-12
8-K 2019-06-05
8-K 2019-06-04
8-K 2019-05-21
8-K 2019-05-13
8-K 2019-05-03
8-K 2019-04-16
8-K 2019-04-15
8-K 2019-04-03
8-K 2019-03-18
8-K 2019-02-14
8-K 2019-01-23
8-K 2019-01-22
8-K 2018-11-13
8-K 2018-11-08
8-K 2018-09-07
8-K 2018-08-24
8-K 2018-06-13
8-K 2018-04-27
8-K 2018-04-16
8-K 2018-04-05
8-K 2018-03-26
8-K 2018-03-16
8-K 2018-02-28
8-K 2018-02-05
8-K 2017-09-30

Sorrento Therapeutics Financials

SRNE Metrics, Comps, Filings

Quarterly | Annual

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
IQVIA Holdings (IQV) 29,724,125 17% 26.0 1% 22,892,000 16,498,000 10,881,000 1,877,000 283,000 1,557,000 40,466,125
Incyte (INCY) 15,859,541 71% 30.0 13% 3,214,818 792,291 2,107,772 1,497,336 404,964 472,286 14,156,523
Exact Sciences (EXAS) 11,943,245 74% -66.8 -12% 1,759,268 1,010,984 723,699 537,965 -215,912 -163,250 10,908,911
PRA Health Sciences (PRAH) 6,887,830 0% 20.6 7% 3,500,456 2,553,713 2,995,670 0 239,843 393,463 8,097,573
Icon (ICLR) 6,885,543 0% 2,354,255 999,974 0 0 0 0 6,489,692
Charles River (CRL) 6,858,681 9% 19.4 5% 4,582,562 3,017,830 2,531,618 226,417 233,214 440,966 8,574,554
Syneos Health (SYNH) 5,712,092 22% 20.1 1% 7,377,313 4,509,797 3,462,861 744,856 85,878 413,220 8,291,749
Exelixis (EXEL) 5,678,154 91% 8.0 34% 1,784,865 181,148 956,067 873,761 612,358 679,272 5,434,837
Medpace Holdings (MEDP) 3,202,354 32% 24.2 9% 1,072,329 380,322 823,198 260,409 93,391 129,245 3,123,064
National Research (NRC) 1,586,160 0% 46.0 22% 107,649 78,674 95,359 0 23,708 35,052 1,614,113
Intrexon (XON) 897,066 0% -2.2 -82% 604,905 376,484 125,549 0 -493,574 -462,730 1,022,820
Sorrento Therapeutics (SRNE) 297,743 28% -2.3 -50% 560,875 554,206 25,327 7,031 -279,022 -243,276 564,852
Luna Innovations (LUNA) 179,849 49% 21.8 5% 82,888 17,979 64,606 31,377 4,136 7,265 158,434
Anavex Life Sciences (AVXL) 175,852 -5.8 -104% 25,329 5,040 0 0 -26,295 -26,295 153,666
Eloxx Pharmaceuticals (ELOX) 174,702 -4.3 -58% 68,057 22,829 0 0 -39,241 -39,241 167,507
Pieris Pharmaceuticals (PIRS) 118,038 0% -1.3 -21% 116,751 96,109 29,009 0 -24,698 -24,698 31,838
Bioanalytical Systems (BASI) 42,778 30% 22.2 -2% 41,980 31,270 43,616 12,920 -790 2,573 57,052
Cleveland Biolabs (CBLI) 11,863 0% -5.2 -87% 2,229 566 547 0 -1,940 -1,929 9,963
Tenax Therapeutics (TENX) 3,371 -0.6 72% 7,774 1,237 0 0 5,603 5,606 -3,278
Nanoviricides (NNVC) 694 0.0 -69% 11,786 2,657 0 0 -8,144 -7,625 -181

Balance Sheet ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash2,9222,2703,4672,4437,6256,4455,0919,6395,7556,43031,66729,94950,15544,26971,90260,50151,69959,06739,03820,81398,17966,48082,39833,91953,68138,32320,42924,25246,784180,441213,330145,713116,12789,391
Accounts Receivable
Inventory4,5686,6314,335
PP&E8509289881,1631,1671,2711,9601,5501,4491,6623,3722,3592,3492,3603,9642,5402,8243,8139,9637,4369,20310,08317,63022,64824,85827,22728,72330,21631,88135,01639,67146,25950,09150,944
Assets3,8963,3114,5693,7258,9177,8926,78212,1987,78937,98392,58290,615110,320104,129141,541131,257132,816325,295343,519273,779351,404279,058401,586345,228384,768484,784431,613436,879452,521587,964624,087609,474587,043560,875
Accounts Payable2032372252002763954407077361,4082,1541,1741,2671,4891,6561,8862,4741,6191,3393,1394,4231,3778,28211,6079,64112,9849,9119,0149,94117,20313,81714,65224,88626,750
Long-Term Debt8768768274,7854,80512,00312,05012,10112,14612,19311,48110,3689,2298,0626,8685,64647,31626,08326,54126,9825,2117,09517,714173,766361,800353,900350,900356,500
Liabilities4254723593204165445841,8742,0197,10425,77331,46532,29633,13932,82831,25741,562178,510202,581184,816216,176206,564315,084283,122288,572346,475225,003196,006193,056364,404416,587491,361532,427554,206
Stockholders' Equity3,4712,8394,2093,4058,5027,3476,19710,3245,77030,87966,80959,15078,02470,990108,713100,00091,254146,189145,15294,814142,24379,65680,03757,78092,422131,021199,568234,805254,371221,592209,472131,94383,52945,895
Income Statement ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue7492128110217135122134142841019767751,2767989771,1731,1031,3379889022,2434,0194,8744,665121,91020,4076,2463,9134,1056,9296,1436,4775,778
Cost of Revenue563510527443509314604523359295418-2611,0648161,0859801,3111,2262,1772,3083,281
Gross Profit4132657493554688594998146296071,8254,2803,8103,849120,82519,4274,9352,6871,9283,8353,196
R&D6366367097999179511,1631,3992,1412,0823,3956,1079,3345,4407,1277,8407,97124,068-5513,00032,00010,212014,88311,17916,60412,86514,63217,92519,56725,58424,75927,573
SG&A5271591822192454277161,2501,5081,1152,5653,3852,3611,8542,3872,2193,0724,71110,1304,4954,2205,26710,23711,8879,09210,2147,1389,96111,03920,10225,12227,77225,234
Tax000100100060000-1735,3231,1861001-1,696-1,39857,480-90,424-948-1,3770-178-3830
Net Income-1,088-702-762-906-943-1,241-1,755-2,522-4,737-3,356-11,296-10,093-8,454-7,605-8,505-10,438-10,958-939-23,476-18,390-44,94914,373-11,957-23,064-14,18737,47348,444-32,574-73,864-47,328-49,774-108,071-56,762-64,415
Cash Flow ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-590-539-798-671-999-1,329-2,482-3,815-2,981-7,211-9,124-6,388-5,596-8,8471,295-18,355-16,162-20,186-12,176-21,767-16,763-21,914-19,750-12,664-23,963-22,122-44,309-46,834-45,831
Cash Investing-61-241-225-85-180-57-207-21-516241-94-104-10,158-1,843-10,15726,309-1,757-596-1,634-2,808-12,414-4,161-6,179-4,588-448-2,364-22,268-2,260-3,256
Cash Financing01,97605,9380327,237-494,17332,2077,500-5545,447-71160-586-2,1102,55791,176-7,12445,131-22,48245,5982,04628,23347,171-1,09719,50322,569